ROCKLAND, Mass., October 10, 2023 EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new analyses from the MAVENCLAD® (cladribine) tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis (RMS) experienced sustained reduction in serum neurofilament light chain (NfL), indicating that MAVENCLAD reduced neuronal injury over two years. Additional data include two real-world evi
ROCKLAND, Mass., October 05, 2023 EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced a new collaboration with the United Nations-Guided Global Initiative on Ageing (GIA) to provide a training course on critical skills for family caregivers. The course, consisting of 5 modules, provides professional instruction and guidance on essential topics in caregiving such as using medical equipment, creating safe environments and overcoming communic
/CNW/ - In collaboration with Bladder Cancer Canada, EMD Serono and Pfizer Canada announced today their selection of two inaugural grant recipients for.
/CNW/ - In the newest analysis from The Carer Well-Being Index, as part of EMD Serono s Embracing Carers® Initiative, 72 per cent of cancer caregivers in.